In a major breakthrough in cellular therapy, FDA has approved the first tumor-infiltrating lymphocyte therapy for patients with unresectable or metastatic melanoma who have received prior treatment, including with checkpoint inhibitors.
On the evening of Feb. 15, when the dreaded letter of termination arrived, an NCI employee was just a few weeks away from job security—the end of the probationary period.
